Literature DB >> 21266919

Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma.

Steven Chuan-Hao Kao1, Tristan D Yan, Kenneth Lee, Juliet Burn, Douglas W Henderson, Sonja Klebe, Catherine Kennedy, Janette Vardy, Stephen Clarke, Nico van Zandwijk, Brian C McCaughan.   

Abstract

INTRODUCTION: Histological subtype is an established prognostic factor in malignant pleural mesothelioma (MPM). We retrospectively investigated the accuracy of classifying histological subtype on diagnostic biopsies and examined the impact of different diagnostic procedures on the outcome.
METHODS: Consecutive patients with histologically confirmed MPM who underwent extrapleural pneumonectomy (EPP) from 1994 to 2009 were included. Patient records were reviewed, and the initial diagnoses of histological subtype were obtained. The archival EPP specimens were reviewed by a panel of pathologists. The histological subtype obtained at review was compared with the initial diagnosis.
RESULTS: Eighty-five patients underwent EPP. Two patients achieved a pathological complete response after neoadjuvant chemotherapy, leaving 83 patients to be included in this review. Different diagnostic methods were used before EPP: 81% thoracoscopy; 7% thoracotomy; 11% computed tomography-guided procedure; and 1% other. Patients determined to have an epithelial subtype (n = 64) at EPP were diagnosed correctly at initial diagnostic biopsy in 84% of cases, whereas patients considered to have a biphasic subtype (n = 19) at EPP were diagnosed correctly at diagnostic biopsy in 26% of cases. The sensitivity and specificity of diagnostic biopsy for epithelial MPM was 93% and 31%, respectively. The overall subtype misclassification rate was 20%. Biopsy by thoracotomy was most accurate in subtype classification (83%) compared with thoracoscopy (74%) and computed tomography-guided procedure (44%).
CONCLUSIONS: The determination of histological subtype from a diagnostic biopsy is difficult due to sampling error, but an adequate specimen obtained from surgical biopsy increases the accuracy of subtype classification compared with radiological-guided biopsies.

Entities:  

Mesh:

Year:  2011        PMID: 21266919     DOI: 10.1097/JTO.0b013e31820ce2c7

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  11 in total

1.  Malignant Mesothelioma Diagnosed by Bronchoscopic Biopsy.

Authors:  Yeon-Hee Park; Jae-Woo Choi; Sang-Ok Jung; Min-Ji Cho; Da-Hyun Kang; Chae-Uk Chung; Dong-Il Park; Jae-Young Moon; Hee-Sun Park; Sung-Soo Jung; Ju-Ock Kim; Sun-Young Kim; Jeong-Eun Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-06-30

Review 2.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

3.  Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.

Authors:  Lucian R Chirieac; Yin P Hung; Wai Chin Foo; Matthias D Hofer; Paul A VanderLaan; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Cancer       Date:  2019-08-07       Impact factor: 6.860

Review 4.  Novel insights into mesothelioma biology and implications for therapy.

Authors:  Timothy A Yap; Joachim G Aerts; Sanjay Popat; Dean A Fennell
Journal:  Nat Rev Cancer       Date:  2017-07-25       Impact factor: 60.716

5.  Cytological Diagnostic Procedures in Malignant Mesothelioma.

Authors:  Christian Biancosino; Lea Isabell Shari van der Linde; Guido Sauter; Florian Stellmacher; Marcus Krüger; Lutz Welker
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR).

Authors:  Andrew Churg; Richard Attanoos; Alain C Borczuk; Lucian R Chirieac; Françoise Galateau-Sallé; Allen Gibbs; Douglas Henderson; Victor Roggli; Valerie Rusch; Meagan J Judge; John R Srigley
Journal:  Arch Pathol Lab Med       Date:  2016-03-31       Impact factor: 5.534

7.  Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?

Authors:  Joanna G Escalon; Kate A Harrington; Andrew J Plodkowski; Junting Zheng; Marinela Capanu; Marjorie G Zauderer; Valerie W Rusch; Michelle S Ginsberg
Journal:  J Comput Assist Tomogr       Date:  2018 Jul/Aug       Impact factor: 1.826

8.  miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.

Authors:  Marissa Williams; Michaela B Kirschner; Yuen Yee Cheng; Jacky Hanh; Jocelyn Weiss; Nancy Mugridge; Casey M Wright; Anthony Linton; Steven C Kao; J James B Edelman; Michael P Vallely; Brian C McCaughan; Wendy Cooper; Sonja Klebe; Ruby C Y Lin; Himanshu Brahmbhatt; Jennifer MacDiarmid; Nico van Zandwijk; Glen Reid
Journal:  Oncotarget       Date:  2015-09-15

9.  Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.

Authors:  Caterina Ledda; Paola Senia; Venerando Rapisarda
Journal:  Cancers (Basel)       Date:  2018-06-15       Impact factor: 6.639

10.  Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor.

Authors:  James Benjamin Gleason; Basheer Tashtoush; Maria Julia Diacovo
Journal:  Case Rep Pulmonol       Date:  2016-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.